Can we incorporate MRD assessment into clinical practice in AML?

Gert Ossenkoppele; Gerrit Jan Schuurhuis; Arjan van de Loosdrecht; Jacqueline Cloos

doi:10.1016/j.beha.2019.05.003

Can we incorporate MRD assessment into clinical practice in AML?

Best Pract Res Clin Haematol. 2019 Jun;32(2):186-191. doi: 10.1016/j.beha.2019.05.003. Epub 2019 May 10.

Authors

Gert Ossenkoppele¹, Gerrit Jan Schuurhuis², Arjan van de Loosdrecht², Jacqueline Cloos²

Affiliations

¹ Amsterdam University Medical Center, Location VUMC, De Boelelaan 1117, 1081, HV, Amsterdam, the Netherlands. Electronic address: g.ossenkoppele@vumc.nl.
² Amsterdam University Medical Center, Location VUMC, De Boelelaan 1117, 1081, HV, Amsterdam, the Netherlands.

PMID: 31204000
DOI: 10.1016/j.beha.2019.05.003

Abstract

Measurable residual disease (MRD) can be assessed either by flow cytometry or molecular techniques. It has been proven to be highly prognostic in quite a number of prospective clinical studies. The recently published ELN MRD recommendations aim harmonize the approaches to MRD assessment in order to improve its overall quality. The predictive value leading to the usage as a surrogate endpoint for survival which would be instrumental for faster drug approvals has still to be proven. Nevertheless, many AML centers use MRD status to inform treatment.

Keywords: AML; Allogeneic stem cell transplantation; Leukemic stem cells; Measurable residual disease (MRD); Multicolor flowcytometry; qPCR.

Publication types

Review

MeSH terms

Clinical Trials as Topic
Disease-Free Survival
Humans
Leukemia, Myeloid, Acute* / metabolism
Leukemia, Myeloid, Acute* / mortality
Leukemia, Myeloid, Acute* / pathology
Leukemia, Myeloid, Acute* / therapy
Neoplasm, Residual
Quality of Health Care*
Survival Rate